Cargando…

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT

Detalles Bibliográficos
Autores principales:	Szer, Jeff, Panse, Jens, Kulasekararaj, Austin, Oliver, Monika, Fattizzo, Bruno, Nishimura, Jun-Ichi, Szamosi, Johan, Horneff, Regina, Peffault de Latour, Régis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430658/ http://dx.doi.org/10.1097/01.HS9.0000970028.58190.a6

Ejemplares similares

PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: de Latour, Régis Peffault, et al.
Publicado: (2023)

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S.M.
Publicado: (2022)

P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
por: Bogdanovic, Andrija, et al.
Publicado: (2023)

P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA
por: Risitano, A., et al.
Publicado: (2022)

Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
por: Shah, Sangam, et al.
Publicado: (2022)

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
por: Fishman, Jesse, et al.
Publicado: (2023)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL
por: Panse, J., et al.
Publicado: (2022)

The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022)

PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS
por: Kelly, Richard, et al.
Publicado: (2023)

P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS
por: Kulasekararaj, A., et al.
Publicado: (2022)

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report
por: Quinquenel, Anne, et al.
Publicado: (2017)

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
por: Risitano, Antonio M., et al.
Publicado: (2019)

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A
Publicado: (2022)

Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report
por: Sharma, Vivek, et al.
Publicado: (2023)

Normalisation of haemoglobin and control of breakthrough haemolysis with increased frequency pegcetacoplan dosing in treated paroxysmal nocturnal haemoglobinuria
por: Davis, Amanda K., et al.
Publicado: (2023)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023)

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
por: Brodsky, Robert A., et al.
Publicado: (2020)

Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A.
Publicado: (2023)

Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Cerebral Venous Thrombosis in Paroxysmal Nocturnal Hemoglobinuria: A Series of 15 Cases and Review of the Literature
por: Meppiel, Elodie, et al.
Publicado: (2015)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

P838: PEGCETACOPLAN RAPIDLY STABILIZES COMPLEMENT INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA EXPERIENCING HEMOLYSIS WITH ACUTE HEMOGLOBIN DECREASES; PRINCE TRIAL POST HOC ANALYSIS
por: Wong, R., et al.
Publicado: (2022)

P839: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN SHOW IMPROVEMENTS IN D-DIMER NORMALIZATION AND DECREASE IN INCIDENCE OF THROMBOSIS
por: Weitz, I., et al.
Publicado: (2022)

Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Myasthenia gravis and paroxysmal nocturnal hemoglobinuria after thymectomy: A rare association
por: Galtier, Jean, et al.
Publicado: (2021)

Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria
por: Luzzatto, Lucio
Publicado: (2016)

Diagnostic and Treatment Challenges of Paroxysmal Nocturnal Hemoglobinuria in Uganda
por: Lumori, Boniface Amanee Elias, et al.
Publicado: (2019)

Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
por: Bektas, Meryem, et al.
Publicado: (2020)

Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective
por: Fattizzo, Bruno, et al.
Publicado: (2022)

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy
por: Barcellini, Wilma, et al.
Publicado: (2020)

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ahcrevq9iqb824pus2jl8o24gd